| 1. |
D?hner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017, 129(4): 424-447.
|
| 2. |
Anzalone CL, Cohen PR. Acute febrile neutrophilic dermatosis (Sweet’s syndrome). Curr Opin Hematol, 2013, 20(1): 26-35.
|
| 3. |
Cohen PR. Sweet’s syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis, 2007, 2: 34.
|
| 4. |
Goodfellow A, Calvert H. Sweet’s syndrome and acute myeloid leukaemia. Lancet, 1979, 2(8140): 478-479.
|
| 5. |
Burton JL. Sweet’s syndrome, pyoderma gangrenosum and acute leukaemia. Br J Dermatol, 1980, 102(2): 239.
|
| 6. |
Cohen PR, Kurzrock R. Sweet’s syndrome and malignancy. Am J Med, 1987, 82(6): 1220-1226.
|
| 7. |
Del Pozo J, Martínez W, Pazos JM, et al. Concurrent Sweet’s syndrome and leukemia cutis in patients with myeloid disorders. Int J Dermatol, 2005, 44(8): 677-680.
|
| 8. |
Paydas S. Sweet’s syndrome: a revisit for hematologists and oncologists. Crit Rev Oncol Hematol, 2013, 86(1): 85-95.
|
| 9. |
Sanchez-Correa B, Bergua JM, Campos C, et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine, 2013, 61(3): 885-891.
|
| 10. |
Ruutu P, Ruutu T, Repo H, et al. Defective neutrophil migration in monosomy-7. Blood, 1981, 58(4): 739-745.
|
| 11. |
Brubaker LH, Essig LJ, Mengel CE. Neutrophil life span in paroxysmal nocturnal hemoglobinuria. Blood, 1977, 50(4): 657-662.
|
| 12. |
Magro CM, De Moraes E, Burns F. Sweet’s syndrome in the setting of CD34-positive acute myelogenous leukemia treated with granulocyte colony stimulating factor: evidence for a clonal neutrophilic dermatosis. J Cutan Pathol, 2001, 28(2): 90-96.
|
| 13. |
Magro CM, Kiani B, Li J, et al. Clonality in the setting of Sweet’s syndrome and pyoderma gangrenosum is not limited to underlying myeloproliferative disease. J Cutan Pathol, 2007, 34(7): 526-534.
|
| 14. |
Bidyasar S, Montoya M, Suleman K, et al. Sweet syndrome associated with granulocyte colony-stimulating factor. J Clin Oncol, 2008, 26(26): 4355-4356.
|
| 15. |
閻嶂松, 李大鵬, 姜爾烈, 等. 全反式維甲酸治療急性早幼粒細胞白血病并發Sweet’s綜合征(附一例報告并文獻復習). 中華血液學雜志, 2007, 28(7): 462-465.
|
| 16. |
Liu Y, Tabarroki A, Billings S, et al. Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine. Leuk Lymphoma, 2014, 55(2): 447-449.
|
| 17. |
Trickett HB, Cumpston A, Craig M. Azacitidine-associated Sweet’s syndrome. Am J Health Syst Pharm, 2012, 69(10): 869-871.
|
| 18. |
Sexauer A, Perl A, Yang XC, et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITDAML. Blood, 2012, 120(20): 4205-4214.
|
| 19. |
Buck T, González LM, Lambert WC, et al. Sweet’s syndrome with hematologic disorders: a review and reappraisal. Int J Dermatol, 2008, 47(8): 775-782.
|
| 20. |
Kazmi SM, Pemmaraju N, Patel KP, et al. Characteristics of Sweet syndrome in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk, 2015, 15(6): 358-363.
|
